These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25341705)

  • 1. Stent thrombosis: a clinical perspective.
    Claessen BE; Henriques JP; Jaffer FA; Mehran R; Piek JJ; Dangas GD
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1081-92. PubMed ID: 25341705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy management in patients with coronary stent undergoing vascular surgery.
    Bozzani A; Ferlini M; Rossini R; Musumeci G; Arici V; Bramucci E; Setacci C
    J Cardiovasc Surg (Torino); 2015 Aug; 56(4):681-3. PubMed ID: 25008060
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
    Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The saga of the duration of dual antiplatelet therapy after drug-eluting stent placement.
    Helft G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):469-71. PubMed ID: 26432274
    [No Abstract]   [Full Text] [Related]  

  • 5. Should all stent patients have prolonged dual antiplatelet therapy?
    Kirtane AJ; King SB
    JACC Cardiovasc Interv; 2015 May; 8(6):873-875. PubMed ID: 25999115
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy in patients with coronary stent undergoing urologic surgery: is it still no man's land?
    Naspro R; Rossini R; Musumeci G; Gadda F; Pozzo LF
    Eur Urol; 2013 Jul; 64(1):101-5. PubMed ID: 23428067
    [No Abstract]   [Full Text] [Related]  

  • 9. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy.
    Galli M; Andreotti F; D'Amario D; Vergallo R; Montone RA; Porto I; Crea F
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):128-129. PubMed ID: 31309231
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions.
    Capodanno D; Angiolillo DJ
    JACC Cardiovasc Interv; 2017 Mar; 10(5):425-437. PubMed ID: 28279311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
    Kim YS; Lee SR
    Tex Heart Inst J; 2015 Oct; 42(5):483-6. PubMed ID: 26504448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will We Ever Decide What Antithrombotic Regimen to Use After Stenting?
    King SB
    Cardiovasc Revasc Med; 2020 May; 21(5):702-703. PubMed ID: 32600799
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview.
    Rubboli A; Faxon DP; Juhani Airaksinen KE; Schlitt A; Marín F; Bhatt DL; Lip GY
    Thromb Haemost; 2014 Dec; 112(6):1080-7. PubMed ID: 25298351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S; Hoffmeister HM; Bode C
    Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.